- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00002852
Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To determine if adjuvant chemotherapy can favorably alter the prognosis of the subgroup of resected stage I patients who, following complete surgical resection of their disease, are defined as "high risk" based on the presence of a T2N0 tumor (according to the criteria of the International Staging System for lung cancer).
SECONDARY OBJECTIVES:
I To compare failure-free survival of patients with T2N0 stage I NSCLC who have and have not been treated with adjuvant chemotherapy.
II. To determine the toxicities associated with adjuvant chemotherapy. III. To describe the pattern of disease recurrence.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to tumor histology (squamous cell vs nonsquamous cell), degree of differentiation (poorly differentiated vs other), and mediastinal node sampling at surgery (yes vs no). Within 4-8 weeks after surgery, patients are randomized to 1 of 2 treatment arms.
Arm I:Patients receive no further therapy.
Arm II: Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1. Treatment continues every 3 weeks for 4 courses.
Patients are followed every 4 months for 2 years and then every 6 months thereafter.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60606
- Cancer and Leukemia Group B
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically documented non-small cell carcinoma
- Completely resected T2N0M0 Stage I NSCLC as defined by the International Staging System
- Surgery shall consist of a lobectomy or pneumonectomy with resection of associated N1 lymph nodes (either by thoracotomy or thoracoscopy)
- Patients must be randomized within 4 to 8 weeks from the date of complete surgical resection
- No prior chemotherapy or radiation for non-small cell lung cancer
- Performance status of 0 or 1
- Women must be non-pregnant and non-lactating; patients of childbearing potential must agree to use an effective form of contraception while on study
- Patients must have no history of previous or concomitant malignancy, other than curatively treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin, or surgically treated in situ carcinoma of the breast, or other cancer for which the patient has bee disease free for five years
- Granulocytes >= 1,800/ul
- Platelets >= 100,000/ul
- Bilirubin < 1.5 mg/dl
- SGOT (AST) < 2.0 x ULN
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Arm I (surgery, observation)
Patients receive no further therapy.
|
Gennemgå operation
|
Eksperimentel: Arm II (surgery, chemotherapy)
Patients receive adjuvant therapy comprising paclitaxel IV over 3 hours followed by carboplatin IV over 1-2 hours on day 1.
Treatment continues every 3 weeks for 4 courses.
|
Givet IV
Andre navne:
Givet IV
Andre navne:
Gennemgå operation
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Overall survival (OS)
Tidsramme: Up to 2.4 years
|
OS curves will be calculated using the Kaplan-Meier life-table method.
Comparison of the survival curve for the two treatment regimens will be performed using the log-rank test for censored data.
|
Up to 2.4 years
|
Failure-free survival
Tidsramme: Time between randomization and disease relapse or death, assessed up to 2.4 years
|
Failure-free survival curves will be calculated using the Kaplan-Meier life-table method.
|
Time between randomization and disease relapse or death, assessed up to 2.4 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Toxicity as assessed by Common Toxicity Criteria version 2.0
Tidsramme: Up to 1 year after completion of treatment
|
Up to 1 year after completion of treatment
|
|
Pattern of disease recurrence.
Tidsramme: Up to 2 years
|
The frequency of local and distant relapse and the incidence of a second primary lung cancer will be tabulated by treatment.
|
Up to 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Gary Strauss, Cancer and Leukemia Group B
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Neoplasmer
- Lungesygdomme
- Neoplasmer efter sted
- Adenocarcinom
- Karcinom
- Neoplasmer, kirtel og epitel
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Adenocarcinom i lunge
- Adenocarcinom, bronchiolo-alveolær
- Molekylære mekanismer for farmakologisk virkning
- Antineoplastiske midler
- Tubulin modulatorer
- Antimitotiske midler
- Mitose modulatorer
- Antineoplastiske midler, fytogene
- Carboplatin
- Paclitaxel
Andre undersøgelses-id-numre
- NCI-2012-02967
- U10CA031946 (U.S. NIH-bevilling/kontrakt)
- CALGB-9633
- CDR0000065095
- CLB-C9633
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Planocellulær lungekræft
-
AHS Cancer Control AlbertaCross Cancer InstituteAfsluttetOmfattende Stage Small Cel Lung CancerCanada
Kliniske forsøg med paclitaxel
-
Anne NoonanNational Cancer Institute (NCI)RekrutteringStadie IV Bugspytkirtelkræft AJCC v8 | Metastatisk bugspytkirteladenokarcinomForenede Stater
-
City of Hope Medical CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbagevendende brystkarcinom | Stage IV brystkræft AJCC v6 og v7 | Fase III brystkræft AJCC v7 | Fase IIIA Brystkræft AJCC v7 | Fase IIIB Brystkræft AJCC v7 | Stage IIIC brystkræft AJCC v7 | Metastatisk brystkarcinom | Lokalt avanceret brystkarcinomForenede Stater
-
Mayo ClinicNational Cancer Institute (NCI)Trukket tilbageTilbagevendende blære-urothelial carcinom | Stadie IV Blære Urothelial CarcinomForenede Stater
-
Shengjing HospitalRekruttering
-
Hutchison Medipharma LimitedSun Yat-sen UniversityAktiv, ikke rekrutterende
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationAfsluttetTilbagevendende ikke-småcellet lungekarcinom | Stadie IV ikke-småcellet lungekræftForenede Stater
-
CTI BioPharmaAfsluttetNSCLCForenede Stater, Canada, Bulgarien, Rumænien, Den Russiske Føderation, Ukraine, Mexico, Argentina, Ungarn, Polen, Det Forenede Kongerige
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeAnatomisk fase I brystkræft AJCC v8 | Anatomisk fase IA brystkræft AJCC v8 | Anatomisk fase IB brystkræft AJCC v8 | Anatomisk fase II brystkræft AJCC v8 | Anatomisk fase IIA brystkræft AJCC v8 | Anatomisk fase IIB brystkræft AJCC v8 | Anatomisk fase III brystkræft AJCC v8 | Anatomisk fase IIIA brystkræft... og andre forholdForenede Stater
-
Novartis PharmaceuticalsAfsluttetMetastaserende eller lokalt avancerede solide tumorerHolland, Spanien, Tyskland, Schweiz, Belgien
-
CTI BioPharmaAfsluttet